Genta genta.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform : DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial , a global Phase 3 trial of Genasense in patients...Show all

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform : DNA/RNA-ba...Show all

Company (IPO / Went public)

Phone: 908-286-9800

Fax:

200 Connell Drive

Berkeley Heights, 07922
New Jersey, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Genta $77.5M Jun 23, 2008
See all 41 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Genta Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 19 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Allos Therapeutics

Westminster, Colorado, United States
AcquiredAllos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or ...Show allLogin to see details

Callisto Pharmaceuticals

New York, New York, United States
AcquiredCallisto Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and osteolytic bone disease, among other cancers. The Company's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The Company was formed, in April 2003, through a reverse acquisition between Callisto Pharmaceuticals and Webtronics....Show allLogin to see details
See all 41 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers Dec 16, 2003 Dec 21, 2010 Patent
Pharmaceutical gallium compositions and methods Mar 11, 2008 Nov 30, 2010 Patent
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers Nov 10, 2000 Sep 14, 2010 Patent